 Aicardi-goutieres Syndrome 7; Ags7
	Aicardi-goutieres Syndrome 7; Ags7
Description
Aicardi-Goutieres syndrome-7 is an autosomal dominant inflammatory disorder characterized by severe neurologic impairment. Most patients present in infancy with delayed psychomotor development, axial hypotonia, spasticity, and brain imaging changes, including basal ganglia calcification, cerebral atrophy, and deep white matter abnormalities. Laboratory evaluation shows increased alpha-interferon (IFNA1 ) activity with upregulation of interferon signaling and interferon-stimulated gene expression. Some patients may have normal early development followed by episodic neurologic regression (summary by Rice et al., 2014).For a phenotypic description and a discussion of genetic heterogeneity of Aicardi-Goutieres syndrome, see AGS1 (OMIM ).
Clinical Features
Top most frequent phenotypes and symptoms related to Aicardi-goutieres Syndrome 7; Ags7
- Intellectual disability
- Seizures
- Global developmental delay
- Generalized hypotonia
- Microcephaly
- Growth delay
- Spasticity
- Feeding difficulties
- Hepatomegaly
- Intrauterine growth retardation
And another 33 symptoms. If you need more information about this disease we can help you.
Incidence and onset information
— Currently we don't have prevalence information about this disease (Not enough data available about incidence and published cases.)— The onset for some of the known clinical features related to this disease may vary, including neonatal onset .
Researches and researchers
Currently, we don't have any information about doctors, researches or researchers related to this disease. Please contact us if you would like to appear here.Aicardi-goutieres Syndrome 7; Ags7 Recommended genes panels
| Panel Name, Specifity and genes Tested/covered | 
|---|
|  Hereditary Spastic Paraplegia Panel. By Greenwood Genetic Center Diagnostic Laboratories Greenwood Genetic Center (United States). 
RTN2, SACS, SLC16A2, SLC2A1, KDM5C, SPG11, ATL1, SPAST, SPG7, TFG, ACOX1, TREX1, UCHL1, VAMP1, ERLIN2, CAPN1, BSCL2, SAMHD1, PNPLA6, ERLIN1	, (...)
 View the complete list with 59 more genes 
Specificity
 2 % 
Genes
 100 % | 
|  Dystonia Exome Panel. By Genetic Services Laboratory University of Chicago (United States). 
BCS1L, SCN8A, SCP2, SDHA, SGCE, SLC16A2, SLC20A2, SLC2A1, SLC6A3, SLC6A8, SPR, SQSTM1, STXBP1, SUCLA2, SUOX, SURF1, SYNJ1, TAF1, TBCD, TH	, (...)
 View the complete list with 150 more genes 
Specificity
 1 % 
Genes
 100 % | 
|  IFIH1. By Institute for Human Genetics University Clinic Freiburg (Germany). 
IFIH1
 
Specificity
 100 % 
Genes
 100 % | 
|  Aicardi-Goutieres syndrome (NGS panel for 7 genes). By CGC Genetics (Portugal). 
TREX1, SAMHD1, RNASEH2A, IFIH1, ADAR, RNASEH2C, RNASEH2B
 
Specificity
 15 % 
Genes
 100 % | 
|  Aicardi-Goutières Syndrome Sequencing Panel with CNV Detection. By PreventionGenetics PreventionGenetics (United States). 
TREX1, SAMHD1, RNASEH2A, IFIH1, ADAR, RNASEH2C, RNASEH2B
 
Specificity
 15 % 
Genes
 100 % | 
|  Aicardi-Goutières Syndrome 7 and Singleton-Merton Syndrome 1 via IFIH1 Gene Sequencing with CNV Detection. By PreventionGenetics PreventionGenetics (United States). 
IFIH1
 
Specificity
 100 % 
Genes
 100 % | 
|  Mental retardation - different panels. By Institute of Human Genetics Uniklinik RWTH Aachen (Germany). 
RGS7, RIT1, RMRP, BCS1L, RPL10, RPS6KA3, RRAS, SALL1, SC5D, ATXN10, BLM, SCN1A, SCN2A, SCN8A, SCO2, AIMP1, SDCCAG8, SDHA, SDHB, SGSH	, (...)
 View the complete list with 845 more genes 
Specificity
 1 % 
Genes
 100 % | 
|  Aicardi-Goutieres Syndrome NGS Panel. By MNG Laboratories (Medical Neurogenetics, LLC.) (United States). 
TREX1, SAMHD1, RNASEH2A, IFIH1, ADAR, RNASEH2C, RNASEH2B
 
Specificity
 15 % 
Genes
 100 % | 
You can get up to 16 more panels with our dedicated tool
Learn moreSources and references
You can check the following sources for additional information.
OMIM Rare Disease Search EngineIf you liked this article maybe you will also find interesting the following in-depth articles about other rare diseases, like NEUROBLASTOMA, SUSCEPTIBILITY TO MYOPATHY, TUBULAR AGGREGATE, 1; TAM1 MIDFACE HYPOPLASIA, HEARING IMPAIRMENT, ELLIPTOCYTOSIS, AND NEPHROCALCINOSIS; MFHIEN